Stockscreener 앱 받기
76.79
0.30%
-0.23
전일 마감가:
$77.02
열려 있는:
$77.21
하루 거래량:
1.68M
Relative Volume:
0.38
시가총액:
$44.46B
수익:
$5.54B
순이익/손실:
$4.18B
주가수익비율:
10.97
EPS:
7
순현금흐름:
$623.10M
1주 성능:
-0.47%
1개월 성능:
-1.20%
6개월 성능:
+3.90%
1년 성능:
-15.69%
1일 변동 폭
$76.50
$77.43
1주일 범위
$76.30
$78.53
52주 변동 폭
$58.93
$95.25
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
EW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
76.79 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
|
ABT
Abbott Laboratories
|
134.44 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.32 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.28 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.39 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - MSN
Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments - Law360
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Is Edwards Lifesciences Stock Underperforming the Dow? - MSN
Is Edwards Lifesciences Stock Underperforming The Dow? - Barchart.com
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating - MarketScreener
Leerink Partnrs Has Positive Estimate for EW Q3 Earnings - Defense World
Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating - marketscreener.com
Health Care Slips as Sector Continues to Lag Market -- Health Care Roundup - marketscreener.com
Edwards Lifesciences stock rises following competitor’s exit - Investing.com
Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com
Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech
Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga
Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus
Edwards Lifesciences (EW) Receives Price Target Increase from Citigroup | EW Stock News - GuruFocus
Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com
Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | EW Stock News - GuruFocus
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey
Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing
Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Rating Lowered to Hold at StockNews.com - Defense World
Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post
Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes - Cardiovascular Business
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq
Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com
Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com
FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal
Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey
Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
에드워즈라이프사이언시스 주식 (EW) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wood Larry L | Global President TAVR & Surg |
Jun 16 '25 |
Sale |
75.23 |
8,950 |
673,268 |
206,900 |
0.07%
자본화:
|
볼륨(24시간):